Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics (NASDAQ: ALRN), a biopharmaceutical company focused on orphan pulmonary and fibrosis indications, has announced its participation in the 8th Annual IPF Summit in Boston, MA. Brian Windsor, Ph.D., President and CEO of Aileron, will present on August 21, 2024, at 2:45 PM ET.
The presentation, titled 'Biomarker Strategies in the Clinical Development of LTI-03 in IPF', will be part of the session on Emerging Biology & Early Translation. This session aims to enhance the predictive power of preclinical modeling and improve the transition from bench to bedside for next-generation therapeutics.
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key stakeholders from the biopharmaceutical industry, clinical practice, and academic research globally.
Aileron Therapeutics (NASDAQ: ALRN), un'azienda biofarmaceutica specializzata in indicazioni orfane per patologie polmonari e fibrosi, ha annunciato la sua partecipazione all'8° Summit Annuale IPF che si terrà a Boston, MA. Brian Windsor, Ph.D., Presidente e CEO di Aileron, presenterà il 21 agosto 2024 alle 14:45 ET.
La presentazione, intitolata 'Strategie Biomarcatori nello Sviluppo Clinico di LTI-03 in IPF', farà parte della sessione su Biologia Emergente e Traduzione Precoce. Questa sessione ha l'obiettivo di migliorare il potere predittivo della modellazione preclinica e di facilitare la transizione dal laboratorio al letto del paziente per le terapie della prossima generazione.
Il Summit IPF è la più grande iniziativa di sviluppo farmaceutico per la comunità affetta da fibrosi polmonare, riunendo i principali attori dell'industria biofarmaceutica, della pratica clinica e della ricerca accademica a livello globale.
Aileron Therapeutics (NASDAQ: ALRN), una empresa biofarmacéutica enfocada en indicaciones huérfanas para enfermedades pulmonares y fibrosis, ha anunciado su participación en la 8ª Cumbre Anual de IPF en Boston, MA. Brian Windsor, Ph.D., presidente y CEO de Aileron, presentará el 21 de agosto de 2024 a las 2:45 PM ET.
La presentación, titulada 'Estrategias de Biomarcadores en el Desarrollo Clínico de LTI-03 en IPF', formará parte de la sesión sobre Biología Emergente y Traducción Temprana. Esta sesión tiene como objetivo mejorar el poder predictivo de la modelización preclínica y facilitar la transición del laboratorio a la práctica clínica para las terapias de próxima generación.
La Cumbre de IPF es la iniciativa de desarrollo farmacéutico más grande para la comunidad de fibrosis pulmonar, reuniendo a los principales interesados de la industria biofarmacéutica, la práctica clínica y la investigación académica a nivel mundial.
에일러론 테라퓨틱스 (NASDAQ: ALRN)는 희귀 폐질환 및 섬유증 질환에 집중하는 생물 의약품 회사로, 매사추세츠주 보스턴에서 열리는 제8회 IPF 정상 회의에 참여할 것임을 발표했습니다. 브라이언 윈저, Ph.D.는 에일러론의 회장 겸 CEO로서 2024년 8월 21일 오후 2:45 ET에 발표를 할 예정입니다.
이번 발표의 주제는 'IPF에서 LTI-03의 임상 개발을 위한 바이오마커 전략'이며, 신생 생물학 및 초기 번역 세션의 일환으로 진행됩니다. 이 세션은 전임상 모델링의 예측력을 높이고 차세대 치료제를 위한 실험실에서 임상으로의 전환을 개선하는 것을 목표로 하고 있습니다.
IPF 정상 회의는 폐 섬유증 커뮤니티를 위한 가장 큰 의약품 개발 이니셔티브로, 전 세계 생물 의약품 산업, 임상 실무 및 학술 연구의 주요 이해관계자들을 모으고 있습니다.
Aileron Therapeutics (NASDAQ: ALRN), une entreprise biopharmaceutique axée sur les indications orphelines pour les maladies pulmonaires et la fibrose, a annoncé sa participation à la 8ème Sommet Annuel de l'IPF à Boston, MA. Brian Windsor, Ph.D., Président et CEO d'Aileron, présentera le 21 août 2024 à 14h45 ET.
La présentation, intitulée 'Stratégies de Biomarqueurs dans le Développement Clinique de LTI-03 dans l'IPF', fera partie de la session sur la Biologie Émergente et la Traduction Précoce. Cette session vise à améliorer le pouvoir prédictif de la modélisation préclinique et à faciliter la transition du laboratoire au lit du patient pour les thérapies de nouvelle génération.
Le Sommet IPF est la plus grande initiative de développement de médicaments pour la communauté de la fibrose pulmonaire, réunissant les principaux acteurs de l'industrie biopharmaceutique, de la pratique clinique et de la recherche académique à l'échelle mondiale.
Aileron Therapeutics (NASDAQ: ALRN), ein biopharmazeutisches Unternehmen, das sich auf seltene pulmonale und fibrotische Indikationen spezialisiert hat, hat seine Teilnahme am 8. jährlichen IPF-Gipfel in Boston, MA, bekannt gegeben. Brian Windsor, Ph.D., Präsident und CEO von Aileron, wird am 21. August 2024 um 14:45 Uhr ET präsentieren.
Die Präsentation mit dem Titel 'Biomarker-Strategien in der klinischen Entwicklung von LTI-03 bei IPF' wird Teil der Sitzung über aufkommende Biologie und frühe Translation sein. Diese Sitzung zielt darauf ab, die Vorhersagekraft der präklinischen Modellierung zu verbessern und den Übergang vom Labor zur Klinik für Therapeutika der nächsten Generation zu erleichtern.
Der IPF-Gipfel ist die größte Arzneimittelentwicklungsinitiative für die Gemeinschaft der pulmonalen Fibrose und vereint wichtige Akteure aus der biopharmazeutischen Industrie, der klinischen Praxis und der akademischen Forschung weltweit.
- None.
- None.
Details of the presentation are as follows:
Presentation Title: Biomarker Strategies in the Clinical Development of LTI-03 in IPF
Session: Emerging Biology & Early Translation | Uncovering a Translational Framework of Preclinical Modelling to Enhance the Predictive Power & Navigate from Bench to Bedside for the Next-Gen Therapeutics
Date & Time: Wednesday, August 21, 2024, at 2:45 PM ET
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.
About Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis, with Cohort 2 results expected to be reported in the third quarter this year. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Investor Relations & Media Contact:
Argot Partners
aileron@argotpartners.com
212-600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-at-the-8th-annual-ipf-summit-302225421.html
SOURCE Aileron Therapeutics, Inc.
FAQ
When and where is Aileron Therapeutics (ALRN) presenting at the 8th Annual IPF Summit?
What is the title of Aileron Therapeutics' (ALRN) presentation at the IPF Summit?
Who will be presenting on behalf of Aileron Therapeutics (ALRN) at the IPF Summit?
What is the focus of Aileron Therapeutics' (ALRN) research?
What is the significance of the IPF Summit where Aileron Therapeutics (ALRN) is presenting?
